Go to Content Go to Navigation Go to Navigation Go to Site Search Homepage

Partner With Us

Many of our studies come through PPFA (Planned Parenthood Federation of America) through the Planned Parenthood Research Network (PPRN). The PPRN is a network of research departments at Planned Parenthood affiliates nationwide. We often will work on the same studies, coordinated by PPFA, and we are able to meet and discuss study challenges and successes.

We also partner with sponsors such as pharmaceutical companies or academic organizations for conducting research at PPAZ.

Many sponsors work with us on sexual and reproductive health research studies because they know we are experts in the field.

Partner Organizations

Partner Organizations

  1. Planned Parenthood Research Network
  2. Pharmaceutical Companies
  3. Academic Organizations
  4. Internal Planned Parenthood Arizona Research

Our Facilities 

  • Seven health centers across Arizona serving Flagstaff, the greater Phoenix area, and Tucson
  • Office space and resources
  • Conference rooms
  • Investigational product storage including locking refrigerators and freezers
  • Fully equipped examination rooms

Contact Us:


To contact the PPAZ Clinical Research Department, call us at 520-505-3119, or email us at [email protected]

Completed Studies 

Cue Health Study 

October 2023 - January 2024

The Cue Health Study evaluated the performance of the Cue Chlamydia + Gonorrhea Molecular Test for Swab and urine samples for detection of Chlamydia trachomatis/Neisseria gonorrhea (CT/NG).

University of California San Francisco/Advancing New Standards in Productive Health Study

January 2022 - June 2022

This study, hosted out of our Tempe and Glendale health centers, was done to evaluate a patient's ability to self-select for medical abortion. The data was shared with the UCSF/ANSIRH team for evaluation.

The Self-Selection for Medication Abortion study aims to measure how accurate abortions patients are at assessing their overall eligibility for medication abortion, including gestational age and other contraindications, compared to clinician assessment. This study is part of a group of studies Dr. Daniel Grossman and colleagues at Advancing New Standards in Reproductive Health (ANSIRH) at University of California San Francisco are leading to create evidence and consensus in support of over-the-counter medication abortion.

The study enrolled patients seeking abortion in their first or second trimester before they were seen by a healthcare provider at the site (and before their ultrasound). Enrolled patients completed a 10-minute survey that asked questions about gestational age, contraindications for medication abortion, and basic demographic characteristics including age, race/ethnicity, abortion history, parity, and socioeconomic status (e.g., educational attainment; food and housing insecurity). Participants received a $5 electronic gift card by email for participating in the eligibility screening and an additional $25 electronic gift card for completing the survey. PPAZ research staff recruited 300 patients for the study at Tempe and Glendale sites from January- June 2022.

After completion of the survey, patients’ medical care proceeded as normal at the PPAZ health center, including assessment of gestational age and clinician assessment for other contraindications using evidence-based criteria. Then we collected data about the clinician assessment of eligibility for medication abortion to compare to the patient’s assessment. The ANSIRH team is currently analyzing the data to compare the patient surveys to the clinician assessments. Stay tuned for findings from this study from ANSIRH. https://www.ansirh.org/

Cepheid Study

October 2022 – May 2023

This study hosted out of our Central Phoenix health center, tested the efficacy of new devices for point of care testing for chlamydia and gonorrhea.  Patients presenting for an exam were invited to participate in the study. After consenting, we collected urine, vaginal, endocervical, rectal, and pharyngeal specimens to test on the devices. Results became available in 30 minutes or less. The goal of this study was to gather enough data to determine the device’s ability to identify positive and negative results accurately. If successful, this data can then be presented to the U.S. Food and Drug Administration (FDA) for device approval.  Point of care testing for STIs has the power to decrease transmission rates, decrease the overprescription of antibiotics, increase testing rates, and ultimately create a healthier and safer community.

Planned Parenthood cares about your data privacy. We and our third-party vendors use cookies and other tools to collect, store, monitor, and analyze information about your interaction with our site to improve performance, analyze your use of our sites and assist in our marketing efforts. You may opt out of the use of these cookies and other tools at any time by visiting Cookie Settings. By clicking “Allow All Cookies” you consent to our collection and use of such data, and our Terms of Use. For more information, see our Privacy Notice.

Cookie Settings

Planned Parenthood cares about your data privacy. We and our third-party vendors, use cookies, pixels, and other tracking technologies to collect, store, monitor, and process certain information about you when you access and use our services, read our emails, or otherwise engage with us. The information collected might relate to you, your preferences, or your device. We use that information to make the site work, analyze performance and traffic on our website, to provide a more personalized web experience, and assist in our marketing efforts. We also share information with our social media, advertising, and analytics partners. You can change your default settings according to your preference. You cannot opt-out of required cookies when utilizing our site; this includes necessary cookies that help our site to function (such as remembering your cookie preference settings). For more information, please see our Privacy Notice.



We use online advertising to promote our mission and help constituents find our services. Marketing pixels help us measure the success of our campaigns.



We use qualitative data, including session replay, to learn about your user experience and improve our products and services.



We use web analytics to help us understand user engagement with our website, trends, and overall reach of our products.